SCHEMBL3584439

SCHEMBL3584439

CN1CCN(c2ccc(NC=C3C(=O)Nc4ccc(Cc5ccc(N)cc5)cc43)cc2)CC1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 1/20 0.42
ALDH1A1 P00352 3/20 0.41
KMT2A Q03164 2/20 0.41
MAPT P10636 2/20 0.41
KDM4E B2RXH2 1/20 0.41
GAA P10253 1/20 0.41
ADRA2C P18825 1/20 0.41
GFER P55789 1/20 0.41
PTK2B Q14289 1/20 0.41
ESR2 Q92731 1/20 0.41
FLT3 P36888 3/20 0.39
RET P07949 2/20 0.39
PDGFRB P09619 2/20 0.38
EGFR P00533 1/20 0.37
MEN1 O00255 1/20 0.36
TGM2 P21980 1/20 0.36
TNK2 Q07912 1/20 0.35
NCF1 P14598 1/20 0.35
ERBB2 P04626 1/20 0.34
FGFR1 P11362 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3576548 0.92 CSF1R (0.40) CSF1RKMT2AMAPTADRA2CESR2
SCHEMBL3570305 0.90 PDGFRB (0.44) CSF1RALDH1A1MAPTKDM4ERET
SCHEMBL3584436 0.89 RET (0.43) CSF1RALDH1A1KMT2AMAPTFLT3
SCHEMBL5440194 0.88 CSF1R (0.47) CSF1RALDH1A1KMT2AMAPTKDM4E
SCHEMBL4704567 0.88 CSF1R (0.47) CSF1RALDH1A1KMT2AMAPTKDM4E
SCHEMBL3576546 0.85 PTK2 (0.43) CSF1RALDH1A1KMT2AMAPTESR2
SCHEMBL3576916 0.85 CSF1R (0.46) CSF1RKMT2AMAPTADRA2CESR2
SCHEMBL3581952 0.84 CSF1R (0.43) CSF1RALDH1A1KMT2AMAPTKDM4E
SCHEMBL4705895 0.84 CSF1R (0.45) CSF1RKMT2AMAPTESR2RET
SCHEMBL5434112 0.84 CSF1R (0.45) CSF1RKMT2AMAPTESR2RET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7692005-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-04-06 US claimed
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed
US-7749530-B2 Kinase inhibitors ALLERGAN, INC. (US) 2010-07-06 US disclosed
US-20090208557-A1 Kinase inhibitors ALLERGAN, INC. 2009-08-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090208557-A1 Kinase inhibitors PTK2, MAP3K6, MAP3K20 CSF1R 776/4885ALDH1A1 2605/4885KMT2A 1670/4885
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 CSF1R 877/4885ALDH1A1 2379/4885KMT2A 1569/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.